When Mylan and Perrigo executives had a “very preliminary” discussion a year ago about possibly merging the two generic drug companies, Perrigo was a different company, according to its CEO Joe Papa.
Back then, the over-the-counter medications specialist was doing business in six countries and looking for a way to dramatically expand its reach. Today, after taking over Belgian-based Omega Pharma Invest in March, Perrigo has expanded to 39 countries.
With the expansion problem resolved, Ireland-based Perrigo is now better equipped to deliver strong growth as an independent company, Mr. Papa told investors at a Deutsche Bank health care conference in Boston on Wednesday.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“We believe we have a business that will grow 5 percent to 10 percent organically, ” Mr. Papa said during a presentation devoted almost entirely to answering questions about the company’s rationale for spurning three unsolicited takeover offers in recent weeks from Mylan…. [READ MORE]
By Patricia Sabatini
